Embedding a Sensitive Liquid-Core Waveguide UV Detector into an HPLC-UV System for Simultaneous Quantification of Differently Dosed Active Ingredients during Drug Release.
analytics of extruded filaments
fused filament 3D printing
hot melt extrusion
liquid-core waveguide
low-dosed dosage forms
oral dosage form
personalized medicine
Journal
Pharmaceutics
ISSN: 1999-4923
Titre abrégé: Pharmaceutics
Pays: Switzerland
ID NLM: 101534003
Informations de publication
Date de publication:
14 Mar 2022
14 Mar 2022
Historique:
received:
15
02
2022
revised:
10
03
2022
accepted:
11
03
2022
entrez:
26
3
2022
pubmed:
27
3
2022
medline:
27
3
2022
Statut:
epublish
Résumé
Individual dosing of pharmaceutics and personalized medicine have become important with regard to therapeutic safety. Dose adjustments, biorelevant drug release and combination of multiple active substances in one dosage form for the reduction in polymedication are essential aspects that increase the safety and acceptance of the patient's pharmacotherapy. Therefore, not only innovative drug products but also new analytical methods are needed during the drug development phase and for quality control that can simultaneously determine different active ingredients and cover wide concentration ranges. We investigated a liquid-core waveguide UV absorbance flow cell detector coupled to an existing HPLC-UV system. A Teflon AF 2400 capillary tubing of 20 cm length was connected in series to the HPLC flow line and enabled a lower limit of quantification of 1 ng/mL pramipexole (increase in sensitivity by 20 compared to common 0.9 cm flow cells). This allowed the low-concentration of pramipexole and the higher concentrations of levodopa and benserazide occurring during drug release to be determined in a single chromatographic run within 22.5 min.
Identifiants
pubmed: 35336013
pii: pharmaceutics14030639
doi: 10.3390/pharmaceutics14030639
pmc: PMC8954145
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
J Pharm Biomed Anal. 2007 Aug 15;44(4):991-5
pubmed: 17512691
Eur J Pharm Sci. 2001 May;13(2):123-33
pubmed: 11297896
Analyst. 2011 Aug 21;136(16):3335-42
pubmed: 21743914
J Chromatogr A. 2006 Nov 3;1132(1-2):132-40
pubmed: 16919286
Pharmaceutics. 2010 Nov 01;2(4):351-363
pubmed: 27721362
Nat Clin Pract Cardiovasc Med. 2009 Feb;6(2):112-9
pubmed: 19104518
AAPS PharmSciTech. 2021 Jan 17;22(1):49
pubmed: 33458797
Int J Pharm. 2020 Apr 15;579:119155
pubmed: 32081794
J Pharm Pharm Sci. 2017;20(0):258-269
pubmed: 28810948
Ther Innov Regul Sci. 2021 Nov 26;:
pubmed: 34826120
Farmaco. 2000 Feb;55(2):136-45
pubmed: 10782386
Talanta. 2021 May 1;226:122145
pubmed: 33676696
Pharmaceutics. 2021 Sep 11;13(9):
pubmed: 34575529
Int J Pharm. 2015 Oct 30;494(2):643-650
pubmed: 26235921
Int J Pharm. 2014 Jan 30;461(1-2):105-11
pubmed: 24280018
Pharm Res. 2000 Feb;17(2):183-9
pubmed: 10751033
J Pharm Sci. 1967 Oct;56(10):1238-42
pubmed: 6059440
Int J Pharm. 2015 Oct 30;494(2):657-663
pubmed: 25934428
Int J Pharm. 2022 Mar 25;616:121555
pubmed: 35131358
Int J Pharm. 2016 Aug 20;510(1):336-49
pubmed: 27317988
Anal Chem. 2010 Apr 15;82(8):3394-8
pubmed: 20349997
Neurology. 1979 Dec;29(12):1584-9
pubmed: 574221
Pharmaceutics. 2022 Jan 17;14(1):
pubmed: 35057112
J Neurol Sci. 1999 Feb 1;163(1):25-31
pubmed: 10223406
Eur Heart J. 2018 Sep 1;39(33):3021-3104
pubmed: 30165516
Anal Chem. 2018 Feb 6;90(3):2063-2069
pubmed: 29281880
Anal Sci. 2003 Apr;19(4):517-23
pubmed: 12725385
Mov Disord. 2015 Jan;30(1):64-72
pubmed: 25449210